Sign in

    Caroline DePaulCitigroup Inc.

    Caroline DePaul is a Vice President and Equity Research Analyst at Citigroup Inc., specializing in the coverage of the US retail sector with a focus on specialty and apparel companies. She provides in-depth research and analysis on major retail names such as Gap Inc., Lululemon Athletica, Under Armour, and Urban Outfitters, and is recognized for delivering data-driven insights and investment recommendations that have contributed to strong performance among her buy/sell calls, although specific success rate metrics are not publicly reported. Caroline began her career as an analyst after completing her studies at Cornell University, joining Citi in 2018 and building her expertise in equity research within the consumer space. She holds FINRA Series 7, 63, and 86/87 licenses, demonstrating her regulatory and professional qualifications in securities analysis.

    Caroline DePaul's questions to Lexicon Pharmaceuticals Inc (LXRX) leadership

    Caroline DePaul's questions to Lexicon Pharmaceuticals Inc (LXRX) leadership • Q2 2025

    Question

    Caroline DePaul of Citi, on behalf of Yigal Nochomovitz, inquired about partner Novo Nordisk's plans for the Phase 1 study of LX9851 in obesity, specifically asking about potential combinations with GLP-1 agonists.

    Answer

    SVP & Chief Medical Officer Dr. Craig Granowitz confirmed that discussions with Novo Nordisk align with the market trend toward oral and combination therapies, positioning LX9851 as a strong candidate for use with agents like semaglutide and in triple combinations. CEO Mike Exton added that Novo Nordisk is highly enthusiastic and committed to advancing the program with 'vigor' following the IND filing.

    Ask Fintool Equity Research AI